en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › News › Molecular Background And Identity — Research Overview

Molecular Background And Identity — Research Overview

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-09 · News

This is a working overview of Toll-like receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-09. Anything still debated is marked as such rather than presented as settled.

Molecular Background and Identity

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Background and Biological Role

The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.

The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.

Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular massApproximately 3,108 DaConsistent with a 28-residue acetylated peptide
Residue count28Corresponds to the amino terminal region of prothymosin alpha
Appearance of dry powderWhite to off-white solidSlight variation between lots is normal
Solubility classFreely soluble in waterLow solubility in most organic solvents
Common synonymsThymosin alpha 1, T alpha 1The numeral reflects an early fraction numbering scheme

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Related pages on this site

Analytical Methods and Storage Stability

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.

Molecular Identity Of Thymosin Alpha-1

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

免疫调节机制与信号

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

在信号层面,Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示,它能激活髓样分化因子88依赖的通路,进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答,有助于细胞免疫。然而,具体受体和结合位点尚未完全确定,不同实验模型的结果存在差异。

Notes from published material

== Etymology == Pilonidal means 'nest of hair' and is derived from the Latin words for 'hair' (pilus) and 'nest' (nidus). The condition was first described by Herbert Mayo in 1833. R. M. Hodges was the first to use the phrase pilonidal cyst to describe the condition in 1880. The condition was widespread in the United States Army during World War II. The condition was termed "Jeep seat" or "Jeep riders' disease", because a large portion of people who were being hospitalized for it rode in Jeeps, and prolonged bumpy rides in the vehicles were believed to have caused the condition due to irritation and pressure on the coccyx.

=== Plants === Plants also have receptors that can cause a response to chitin, namely chitin elicitor receptor kinase 1 and chitin elicitor-binding protein. The first chitin receptor was cloned in 2006. When the receptors are activated by chitin, genes related to plant defense are expressed, and jasmonate hormones are activated, which in turn activate systemic defenses. Commensal fungi have ways to interact with the host immune response that, as of 2016, were not well understood. Some pathogens produce chitin-binding proteins that mask the chitin they shed from these receptors.

Melting 20 kg (44 lb) of crystallized honey at 40 °C (104 °F) can take up to 24 hours, while 50 kg (110 lb) may take twice as long. These times can be cut nearly in half by heating at 50 °C (122 °F); however, many of the minor substances in honey can be affected greatly by heating, changing the flavor, aroma, or other properties, so heating is usually done at the lowest temperature and for the shortest time possible.

As of 2024, the Coffee Bean and Tea Leaf has a total of 1,232 stores in 24 countries, including Bahrain, Bangladesh, Brunei, India, Indonesia, Israel, Jordan, Kingdom of Saudi Arabia, Kuwait, Kurdistan, Malaysia, Mongolia, Myanmar, Oman, Pakistan, Panama, Paraguay, Philippines, Qatar, Singapore, South Korea, Sri Lanka, USA, and Vietnam.

Sources: en.wikipedia.org

Further detail

A 2003 publication by the International Atomic Energy Agency confirms the frequent use of most of the tracers above, and says that manganese-56, sodium-24, technetium-99m, silver-110m, argon-41, and xenon-133 are also used extensively because they are easily identified and measured.

Scanning Electron Microscope (SEM) Transmission electron Microscope (TEM) Fourier Transform Infrared Spectroscopy (FTIR) Atomic force microscopy Contact angle meter Zeta potential (streaming potential) X-ray Diffraction (XRD) Liquid–Liquid Displacement Porosimetry (LLDP)

The branched-chain α-ketoacid dehydrogenase complex (BCKDC or BCKDH complex) is a multi-subunit complex of enzymes that is found on the mitochondrial inner membrane. This enzyme complex catalyzes the oxidative decarboxylation of branched, short-chain alpha-ketoacids. BCKDC is a member of the mitochondrial α-ketoacid dehydrogenase complex family, which also includes the pyruvate dehydrogenase complex (PDHC) and alpha-ketoglutarate dehydrogenase complex (OGDC), key enzymes that function in the Krebs cycle, as well as the 2-oxoadipate dehydrogenase complex (OADHC), which plays a critical role in the degradation of the amino acids lysine, hydroxylysine, and tryptophan.

On June 13, 2013, ESPN announced that they would end the broadcast of the ESPN 3D channel by the end of that year and would "...experiment with things like UHDTV." On June 26, 2013, Sharp announced the LC-70UD1U, which is a 70 in (180 cm) 4K Ultra HD TV. The LC-70UD1U is the world's first TV with THX 4K certification. On July 2, 2013, Jimmy Kimmel Live! recorded in 4K Ultra HD a performance by musical guest Karmin, and the video clip was used as demonstration material at Sony stores. On July 3, 2013, Sony announced the release of their 4K Ultra HD Media Player with a price of US$7.99 for rentals and US$29.99 for purchases. The 4K Ultra HD Media Player only worked with Sony's 4K Ultra HD TVs. On July 15, 2013, the CTA published CTA-861-F, a standard that applies to interfaces such as DVI, HDMI, and LVDS. The CTA-861-F standard adds support for several Ultra HD video formats and additional color spaces. On September 2, 2013 Acer announced the first smartphone, dubbed Liquid S2, capable of recording 4K video. On September 4, 2013, the HDMI Forum released the HDMI 2.0 specification, which supports 4K resolution at 60 fps. On the same day, Panasonic announced the Panasonic TC-L65WT600—the first 4K TV to support 4K resolution at 60 FPS. The Panasonic TC-L65WT600 has a 65 in (170 cm) screen, support for DisplayPort 1.2a, support for HDMI 2.0, an expected ship date of October, and a suggested retail price of US$5,999.

== Diagnosis == CIP and CIM are a major cause of ICU-acquired weakness (ICUAW). Current guidelines recommend a clinical diagnosis of ICUAW, made by manually testing the muscle strength with the use of the Medical Research Council (MRC) sum score or handgrip dynamometry. CIP/CIM is often not identified until a patient is unable to be successfully weaned from a mechanical ventilator. Early detection of the condition is difficult, because these patients are often sedated and intubated, and thus unable to cooperate with a thorough neuromuscular physical examination. The use of conventional nerve conduction studies is time-consuming and requires specialized personnel; however, simplified electrophysiologic tests can be used as screening tools in the critically ill to confirm or exclude CIP/CIM. The peroneal nerve test is a validated, high-sensitivity, minimally invasive, non-volitional and quick diagnostic test which can accurately exclude CIP/CIM if the result is normal. Moreover, patients with disuse atrophy and muscle deconditioning have normal electrophysiological tests even if muscle strength is severely reduced Hence, these tests are important to define the cause of muscle weakness and can be helpful to refine the prognosis.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha 1 a hormone?

The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.

Is thymosin alpha-1 a hormone?

It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.

How does it differ from thymosin beta-4?

The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.

Why is the term thymalfasin also used?

Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.

Network